We are an innovative pharmaceutical company determined to improve the lige of people with allergy. We have developed our biotechnology with you in mind. How could we turn on sharp insights on allergy and precision medicine into a better life for you? ANGANY is a private, French-Canadian pharmaceutical company with mission to change our ability to fight allergy. Our goal is to help people with allergies get their life back. Leveraging 30 years of research in biotechnology, immunology and vaccinology, and after more than $ 15M of R&D investments, ANGANY has tackled the specific challenges of allergy to invent a new generation of pharmaceuticals. The goal: treatments worthy of precision medicine, simpler, more effective and safer than current desensitization, and based on a more precise diagnosis.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
In a world first, ANGANY has developed an exclusive vaccine platform based on synthetic biology. This self-adjuvant vector, ANGANY’s proprietary eBioparticle ™, has demonstrated at the preclinical level the possibility of reversing the allergy dynamics. ANGANY has developed a flexible, fast and easy to scale 3rd generation plant-based production platform.
ANGANY thus wishes to bring lasting solutions into a reality where even today allergy sufferers must too often rely on drugs that only mask the symptoms of allergy. ANGANY has developed a form of immunotherapy that is simple in its administration, and from which we expect safety and long-lasting protective effects. Our goal is to stop the allergy dynamic that affects people and prevent the allergic disease from progressing.
ANGANY anticipates that its vaccine platform will also find direct applications in other therapeutic areas such as cancer, in the treatment of autoimmune, infectious and other diseases, in human and animal health.
ANGANY is a Canadian company founded in 2017 and which continues a mission started in France in 2010 by Dr Loïc Faye and Véronique Gomord and their biotech start-up Angany Genetics SAS.
ANGANY inc. is based in Quebec City; the company owns Angany Innovation SAS, an R&D laboratory located at the Pharmaparc de Val-de-Reuil in Normandy. ANGANY inc. is led by Louis-Philippe Vézina PhD, an entrepreneur behind a great Canadian pharmaceutical manufacturing success and a pioneer in plant-based vaccine manufacturing.
Thirty percent of people living in industrialized countries suffer from allergy. Traditional desensitization using allergen extracts has shown its limits. Current symptomatic remedies and/or demanding courses of desensitization bring little hope to those for whom allergy is the unwanted, permanent guest. Little hope for the families struggling with food or pet allergy. In the US alone, the number of people diagnosed with allergy will grow by more than 1 million per year between year 2020 and 2050. This number is in the neighbourhood of 200,000 per year in Canada. It is for them and their families that ANGANY is developing a totally new approach to allergy diagnosis and treatment. We hope this will put an end to the disappointments and anxiety caused by inaccurate diagnoses, to burdensome 3-5 year-long desensitization protocols and perhaps more importantly, to the chronic and often excessive use of OTC and prescription antihistamines and corticosteroids.
ANGANY’s is now preparing a suite of personalized products aiming to redefine both the diagnosis and treatment of allergic diseases and indeed, in many ways help restore your health and let you enjoy life as you did before.
Accurate diagnosis. Short and safe vaccination protocols.
Our hope is that your treasured pet will soon be welcomed by all, pollen will not impede your ability to enjoy the outdoors and food items will no longer threaten lives.
Vision, Expertise, Leadership
Louis-Philippe Vézina, PhD CEO, ANGANY Inc.
Dr. Vézina is a successful entrepreneur and seasoned pharmaceutical executive. He is a scientist with an intimate grasp of plant cell physiology. But in a rare combination of expertise and experience, he also masters industrial scale process development and excels in corporate level leadership.
Dr. Vézina specialized in agriculture and the plant-based production of sophisticated pharmaceutical ingredients. He was a co-founder and former head of scientific development at MEDICAGO, the first pharmaceutical company to develop plant-based influenza vaccines. In this role, he authored several patents. In addition to leading a 100+ R&D team, he was for many years a member of the Board and managed several regulatory agency-supervised assessments.
In addition to his role as CSO, he honed his skills in business development as well as in project management. Throughout his career, he has authored numerous scientific publications on biochemistry, protein sequencing and molecular biology. He was awarded various prizes and awards for his research and his involvement in scientific developments in Canada. Dr. Vézina left MEDICAGO in early 2014. In 2015, he started consulting for Angany Genetics SAS, a France-based biotech start-up. Dr. Vézina is a co-founder of Quebec City-based ANGANY inc. established in 2018 and is leading the company’s efforts in developing a first-in class vaccination vector specifically designed to overcome the challenges of the allergic condition.
Angany Innovation SAS: ANGANY’s R&D lab in Val-de-Reuil, France
Angany Innovation SAS is a French company focused on R&D and wholly-owned by ANGANY Inc. Angany Innovation SAS operates state of the art facilities located at the Pharmaparc in Val-de-Reuil in Normandy, France.
Our COVID-19 effort
ANGANY is joining the COVID-19 effort with its promising novel vaccination technology
The unprecedented social and economic upset caused by the pandemic called for social responsibility. ANGANY’s entire team pitched in to join the fight!
The fight against allergy is at the heart of ANGANY’s mission. And it is to overcome the specific challenges of allergy that ANGANY has developed a new first-in class immunotherapy vaccine. This form of treatment, unprecedented in the field of allergy, draws from synthetic biology and molecular allergology.
The onset of the COVID-19 pandemic, however, called on ANGANY’s team to step up to help. Despite the difficult context of a first containment, the people at ANGANY managed to advance several development projects for its allergy products. The pilot production unit of clinical material was built and put into operation. But beyond this, each one in the team at ANGANY in Quebec and those of Angany Innovation in Val-de-Reuil in Normandy worked in a context of urgency to adapt our biotechnology to the fight against the SARS-CoV-2 virus which causes COVID- 19.
ANGANY is getting involved in the “COVID-19 vaccine race” with a promising vaccine approach that could be particularly useful in certain target groups such as the elderly for example. ANGANY’s 3rd generation plant production platform is also an asset. While complying from the outset with Good Manufacturing Practices (pharmaceutical production standard), it allows quick and easy production scale-up.
ANGANY has received substantial support from the Government of Quebec and its Ministry of Economy and Innovation in its effort against COVID-19. Through a loan from Investissement Québec, ANGANY is encouraged to pursue the development of a vaccine based on its exclusive eBioparticle™ vaccine platform. This new vaccine candidate is under preclinical development. The Angany Innovation R&D team also designed 2 other prototypes of antiviral drugs.
Additionally, ANGANY is participating with a network of globally recognized collaborators in the development of other drug candidates targeting COVID-19. ANGANY sees in its “COVID effort” one more opportunity to contribute to the pharmaceutical effort against this disease and its consequences on health, the economy and society.